Search

Joshua E. Rodden

Examiner (ID: 18569, Phone: (303)297-4258 , Office: P/3649 )

Most Active Art Unit
3649
Art Unit(s)
3637, 3649, 3642, 3631
Total Applications
1250
Issued Applications
711
Pending Applications
85
Abandoned Applications
472

Applications

Application numberTitle of the applicationFiling DateStatus
Array ( [id] => 17436127 [patent_doc_number] => 11261441 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-01 [patent_title] => Vectors and compositions for treating hemoglobinopathies [patent_app_type] => utility [patent_app_number] => 16/496720 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 23111 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 16 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496720 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/496720
Vectors and compositions for treating hemoglobinopathies Mar 28, 2018 Issued
Array ( [id] => 15557441 [patent_doc_number] => 20200063132 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => NUCLEIC ACID MOLECULES AND THEIR METHODS OF USE [patent_app_type] => utility [patent_app_number] => 16/498408 [patent_app_country] => US [patent_app_date] => 2018-03-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19289 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -33 [patent_words_short_claim] => 87 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16498408 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/498408
Regulation of MIR-143 using nucleic acid molecules Mar 28, 2018 Issued
Array ( [id] => 17133738 [patent_doc_number] => 11135274 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-10-05 [patent_title] => MRNA for use in treatment of human genetic diseases [patent_app_type] => utility [patent_app_number] => 15/937359 [patent_app_country] => US [patent_app_date] => 2018-03-27 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 1 [patent_figures_cnt] => 1 [patent_no_of_words] => 10239 [patent_no_of_claims] => 3 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 60 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15937359 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/937359
MRNA for use in treatment of human genetic diseases Mar 26, 2018 Issued
Array ( [id] => 16769697 [patent_doc_number] => 10980779 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2021-04-20 [patent_title] => GFI1 inhibitors for the treatment of hyperglycemia [patent_app_type] => utility [patent_app_number] => 16/496761 [patent_app_country] => US [patent_app_date] => 2018-03-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 18 [patent_no_of_words] => 6600 [patent_no_of_claims] => 1 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16496761 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/496761
GFI1 inhibitors for the treatment of hyperglycemia Mar 25, 2018 Issued
Array ( [id] => 15646545 [patent_doc_number] => 20200085802 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-03-19 [patent_title] => METHOD FOR PREDICTION OF SUSCEPTIBILITY TO SORAFENIB TREATMENT BY USING SULF2 GENE, AND COMPOSITION FOR TREATMENT OF CANCER COMPRISING SULF2 INHIBITOR [patent_app_type] => utility [patent_app_number] => 16/495555 [patent_app_country] => US [patent_app_date] => 2018-03-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 10430 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16495555 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/495555
Method for prediction of susceptibility to sorafenib treatment by using SULF2 gene, and composition for treatment of cancer comprising SULF2 inhibitor Mar 19, 2018 Issued
Array ( [id] => 13314787 [patent_doc_number] => 20180208930 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-26 [patent_title] => TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE [patent_app_type] => utility [patent_app_number] => 15/925266 [patent_app_country] => US [patent_app_date] => 2018-03-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 34638 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -16 [patent_words_short_claim] => 97 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15925266 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/925266
TREATMENT OF LIPID TRANSPORT AND METABOLISM GENE RELATED DISEASES BY INHIBITION OF NATURAL ANTISENSE TRANSCRIPT TO A LIPID TRANSPORT AND METABOLISM GENE Mar 18, 2018 Abandoned
Array ( [id] => 15527753 [patent_doc_number] => 20200056182 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-20 [patent_title] => REGULATION OF GENE EXPRESSION BY APTAMER-MODULATED RNASE P CLEAVAGE [patent_app_type] => utility [patent_app_number] => 16/487587 [patent_app_country] => US [patent_app_date] => 2018-03-02 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 12637 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -26 [patent_words_short_claim] => 51 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487587 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/487587
Regulation of gene expression by aptamer-modulated RNase p cleavage Mar 1, 2018 Issued
Array ( [id] => 16533301 [patent_doc_number] => 10875884 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2020-12-29 [patent_title] => Compositions and methods for modulating angiopoietin-like 3 expression [patent_app_type] => utility [patent_app_number] => 15/905563 [patent_app_country] => US [patent_app_date] => 2018-02-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 147922 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 105 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15905563 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/905563
Compositions and methods for modulating angiopoietin-like 3 expression Feb 25, 2018 Issued
Array ( [id] => 12863092 [patent_doc_number] => 20180179538 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-06-28 [patent_title] => ANTISENSE NUCLEIC ACIDS [patent_app_type] => utility [patent_app_number] => 15/902231 [patent_app_country] => US [patent_app_date] => 2018-02-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11509 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -15 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15902231 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/902231
ANTISENSE NUCLEIC ACIDS Feb 21, 2018 Abandoned
Array ( [id] => 15345889 [patent_doc_number] => 20200010836 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-09 [patent_title] => Regulation of Gene Expression by Aptamer-Mediated Accessibility of Polyadenylation Signals [patent_app_type] => utility [patent_app_number] => 16/487223 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 11885 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 75 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487223 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/487223
Regulation of Gene Expression by Aptamer-Mediated Accessibility of Polyadenylation Signals Feb 20, 2018 Abandoned
Array ( [id] => 12909685 [patent_doc_number] => 20180195070 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-07-12 [patent_title] => Compositions and Methods for Inhibiting Gene Expression of LPA [patent_app_type] => utility [patent_app_number] => 15/901810 [patent_app_country] => US [patent_app_date] => 2018-02-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 32451 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -29 [patent_words_short_claim] => 45 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15901810 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/901810
Compositions and methods for inhibiting gene expression of LPA Feb 20, 2018 Issued
Array ( [id] => 13400439 [patent_doc_number] => 20180251762 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-09-06 [patent_title] => USE OF TRINUCLEOTIDE REPEAT RNAs TO TREAT CANCER [patent_app_type] => utility [patent_app_number] => 15/899974 [patent_app_country] => US [patent_app_date] => 2018-02-20 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 19340 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 72 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15899974 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/899974
Use of trinucleotide repeat RNAs to treat cancer Feb 19, 2018 Issued
Array ( [id] => 15895203 [patent_doc_number] => 20200147120 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-05-14 [patent_title] => FUNCTION INHIBITOR OF SWI/SNF COMPLEXES [patent_app_type] => utility [patent_app_number] => 16/501000 [patent_app_country] => US [patent_app_date] => 2018-02-16 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 21799 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -24 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16501000 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/501000
FUNCTION INHIBITOR OF SWI/SNF COMPLEXES Feb 15, 2018 Abandoned
Array ( [id] => 13958421 [patent_doc_number] => 20190055554 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-21 [patent_title] => COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION [patent_app_type] => utility [patent_app_number] => 15/896379 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 68504 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -25 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15896379 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/896379
COMPOSITIONS AND METHODS FOR MODULATING HBV EXPRESSION Feb 13, 2018 Abandoned
Array ( [id] => 13898705 [patent_doc_number] => 20190038557 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-02-07 [patent_title] => MEANS FOR LUNG SPECIFIC DELIVERY [patent_app_type] => utility [patent_app_number] => 15/897069 [patent_app_country] => US [patent_app_date] => 2018-02-14 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 17449 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -19 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15897069 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/897069
MEANS FOR LUNG SPECIFIC DELIVERY Feb 13, 2018 Abandoned
Array ( [id] => 15557439 [patent_doc_number] => 20200063131 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-02-27 [patent_title] => SYSTEM AND METHOD FOR CELL TYPE-SPECIFIC TRANSLATION OF RNA MOLECULES IN EUKARYOTES [patent_app_type] => utility [patent_app_number] => 16/487377 [patent_app_country] => US [patent_app_date] => 2018-02-09 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 7575 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -12 [patent_words_short_claim] => 168 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16487377 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/487377
System and method for cell type-specific translation of RNA molecules in eukaryotes Feb 8, 2018 Issued
Array ( [id] => 15436181 [patent_doc_number] => 20200032274 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2020-01-30 [patent_title] => POLYNUCLEOTIDE SECONDARY STRUCTURE [patent_app_type] => utility [patent_app_number] => 16/483012 [patent_app_country] => US [patent_app_date] => 2018-02-01 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 28555 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -22 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16483012 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/483012
POLYNUCLEOTIDE SECONDARY STRUCTURE Jan 31, 2018 Abandoned
Array ( [id] => 13387085 [patent_doc_number] => 20180245084 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2018-08-30 [patent_title] => COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS [patent_app_type] => utility [patent_app_number] => 15/876454 [patent_app_country] => US [patent_app_date] => 2018-01-22 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 67757 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -23 [patent_words_short_claim] => 265 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15876454 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/876454
COMPOSITIONS AND METHODS FOR ENHANCED INTESTINAL ABSORPTION OF CONJUGATED OLIGOMERIC COMPOUNDS Jan 21, 2018 Abandoned
Array ( [id] => 17497789 [patent_doc_number] => 11286482 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2022-03-29 [patent_title] => Endosomal cleavable linkers [patent_app_type] => utility [patent_app_number] => 16/474776 [patent_app_country] => US [patent_app_date] => 2018-01-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 39 [patent_figures_cnt] => 10 [patent_no_of_words] => 58772 [patent_no_of_claims] => 19 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 77 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16474776 [rel_patent_id] =>[rel_patent_doc_number] =>)
16/474776
Endosomal cleavable linkers Jan 17, 2018 Issued
Array ( [id] => 13827275 [patent_doc_number] => 20190017122 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2019-01-17 [patent_title] => MIRNAS AS DIAGNOSTIC BIOMARKERS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID TUMORS [patent_app_type] => utility [patent_app_number] => 15/873067 [patent_app_country] => US [patent_app_date] => 2018-01-17 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 0 [patent_figures_cnt] => 0 [patent_no_of_words] => 109286 [patent_no_of_claims] => 0 [patent_no_of_ind_claims] => -14 [patent_words_short_claim] => 2 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 15873067 [rel_patent_id] =>[rel_patent_doc_number] =>)
15/873067
MIRNAS AS DIAGNOSTIC BIOMARKERS TO DISTINGUISH BENIGN FROM MALIGNANT THYROID TUMORS Jan 16, 2018 Abandoned
Menu